Ocular Therapeutix(DE:0OT)
€5.85+0.50 (+1.74%)
DE:0OT
Ocular Therapeutix stock forecast
€5.85
At close:+0.50 (+1.74%)
Ocular Therapeutix (0OT) Stock Forecast & Price Target
5 Followers
0OT Analyst Ratings
Strong Buy
8Buy0Hold0Sell
Based on 8 analysts giving stock ratings to Ocular Therapeutix in the past 3 months
0OT Stock 12 Month Forecast
Average Price Target
€22.40▲(282.96% Upside)Based on 8 Wall Street analysts offering 12 month price targets for Ocular Therapeutix in the last 3 months. The average price target is EUR 22.40 with a high forecast of EUR 27.62 and a low forecast of EUR 12.47. The average price target represents a 282.96% change from the last price of EUR 5.85.
Past 12 Months12 Month ForecastJan2026Oct2026
High€27.62
Average€22.40
Low€12.47
Highest Price TargetHighest€27.62Average Price Target€22.40Lowest Price TargetLowest€12.47
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Yi Chen | H.C. Wainwright | €22.28→€24.95 | buy | 326.48%Upside | Reiterated | 11/10/26 | ||
| Serge Belanger | Needham | €16.04 | buy | 174.17%Upside | Reiterated | 11/10/26 | ||
| Tazeen Ahmad | Bank of America Securities | €24.06 | buy | 311.25%Upside | Reiterated | 11/09/26 | ||
| Lisa Walter | RBC Capital | €26.73 | buy | 356.94%Upside | Reiterated | 11/09/26 | ||
| Biren Amin | Piper Sandler | €27.62 | buy | 372.18%Upside | Reiterated | 10/12/26 | ||
| Alice Nettleton | UBS | €12.47 | buy | 113.24%Upside | Initiated | 10/11/26 | ||
| Lachlan Hanbury Brown | William Blair | ― | buy | ― | Reiterated | 09/25/26 | ||
| William Maughan | Clear Street | €24.95 | buy | 326.48%Upside | Reiterated | 08/18/26 | ||
| Tara Bancroft | TD Cowen | €17.82 | buy | 204.63%Upside | Reiterated | 08/03/26 | ||
| Colleen M. Kusy | Robert W. Baird | €21.38→€26.73 | buy | 356.94%Upside | Reiterated | 06/18/26 | ||
| Clara Dong | Jefferies | €24.95 | buy | 326.48%Upside | Reiterated | 02/17/26 | ||
| Jonathan Wolleben | Citizens JMP | ― | buy | ― | Reiterated | 02/17/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Yi ChenH.C. Wainwright | BuyReiterated€22.28→€24.95 | 11/10/26 | 326.48%Upside | ||
| Serge BelangerNeedham | BuyReiterated€16.04 | 11/10/26 | 174.17%Upside | ||
| Tazeen AhmadBank of America Securities | BuyReiterated€24.06 | 11/09/26 | 311.25%Upside | ||
| Lisa WalterRBC Capital | BuyReiterated€26.73 | 11/09/26 | 356.94%Upside | ||
| Biren AminPiper Sandler | BuyReiterated€27.62 | 10/12/26 | 372.18%Upside | ||
| Alice NettletonUBS | BuyInitiated€12.47 | 10/11/26 | 113.24%Upside | ||
| Lachlan Hanbury BrownWilliam Blair | BuyReiterated | 09/25/26 | ― | ||
| William MaughanClear Street | BuyReiterated€24.95 | 08/18/26 | 326.48%Upside | ||
| Tara BancroftTD Cowen | BuyReiterated€17.82 | 08/03/26 | 204.63%Upside | ||
| Colleen M. KusyRobert W. Baird | BuyReiterated€21.38→€26.73 | 06/18/26 | 356.94%Upside | ||
| Clara DongJefferies | BuyReiterated€24.95 | 02/17/26 | 326.48%Upside | ||
| Jonathan WollebenCitizens JMP | BuyReiterated | 02/17/26 | ― |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Ocular Therapeutix
3 Months
Success Rate17/27 ratings generated profit
63%
Average Return
+15.70%
Copying Jonathan Wolleben's trades and holding each position for 3 Months would result in 62.96% of your transactions generating a profit, with an average return of +15.70% per trade.
1 Year
Success Rate17/27 ratings generated profit
63%
Average Return
+43.61%
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 62.96% of your transactions generating a profit, with an average return of +43.61% per trade.
2 Years
Success Rate22/27 ratings generated profit
81%
Average Return
+94.34%
Copying Jonathan Wolleben's trades and holding each position for 2 Years would result in 81.48% of your transactions generating a profit, with an average return of +94.34% per trade.
0OT Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 14 | 19 | 15 | 18 | 12 |
| Buy | 2 | 3 | 4 | 4 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 16 | 22 | 19 | 22 | 14 |
In the current month, 0OT has received 14 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 0OT average Analyst price target in the past 3 months is 22.40.
0OT Financial Forecast
High€-0.35
Consensus€-0.39
Low€-0.43
0OT Earnings Forecast
Next quarter’s earnings estimate for 0OT is -EUR 0.39 with a range of -EUR 0.43 to -EUR 0.35. The previous quarter’s EPS was -EUR 0.38. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High€14.6M
Consensus€12.3M
Low€11.6M
0OT Sales Forecast
Next quarter’s sales forecast for 0OT is EUR 12.34M with a range of EUR 11.55M to EUR 14.64M. The previous quarter’s sales results were EUR 11.53M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
0OT Stock Forecast FAQ
What is DE:0OT’s average 12-month price target, according to analysts?
Based on analyst ratings, Ocular Therapeutix’s 12-month average price target is €22.40.
What is DE:0OT’s upside potential, based on the analysts’ average price target?
Ocular Therapeutix has 282.96% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Ocular Therapeutix a Buy, Sell or Hold?
Ocular Therapeutix has a consensus rating of Strong Buy, which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.
What is Ocular Therapeutix’s share price target?
The average share price target for Ocular Therapeutix is €22.40. This is based on 8 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €27.62, and the lowest forecast is €12.47. The average share price target represents a 282.96% increase from the current price of €5.85.
What do analysts say about Ocular Therapeutix?
Ocular Therapeutix’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Street analysts.
How can I buy shares of Ocular Therapeutix?
To buy shares of DE:0OT, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
